Husstedt, Imke
Spiesshoefer, Jens
Reinecke, Holger
Giannoni, Alberto
Kahles, Florian
Dreher, Michael
Boentert, Matthias
Tuleta, Izabela
Article History
Received: 15 January 2023
Accepted: 21 February 2023
First Online: 19 April 2023
Declarations
:
: JS has been supported by the Else-Kröner-Fresenius Stiftung (Grant SP A109), by Kommission für Innovative Medizinische Forschung an der Medizinischen Fakultät Muenster (IMF Grant SP 11 18 15), by Deutsche Herzstiftung (DHS Grant S/01/19) and by young investigator research support from Scuola Superiore Sant´Anna Pisa (Curriculum Ph.D. in Translational Medicine) and has received travel grants and lecture honoraria from Astra Zeneca, Boehringer Ingelheim and Chiesi (all) outside the present work. MB has been supported by Sanofi Genzyme outside this work. MB has received speaker honoraria from Sanofi-Genzyme, UCB Pharma, Amicus Therapeutics, ITF Pharma and Loewenstein Medical and consultant fees from Sanofi-Genzyme and Biogen. AG has worked as a Scientific Advisor for Bayer, Berlin, Germany (2020-2021 – development of a new drug acting on peripheral chemoreceptors in heart failure) and Respicardia, Zoll Medical, Minnetonka, MN, US (2021- ongoing, study of phrenic nerve stimulation as a potential treatment for central apneas in heart failure). HR reports personal fees from Daiichi Sankyo, Pfizer, MedUpdate, StreamedUp, DiaPlan, NeoVasc, Pluristem, NovoNordisk and Corvia. Furthermore, institutional grants were received from Pluristem, BMS, Pfizer, Bard and Biotronik. IH, FK, MD and IT report no conflict of interest in the context of the present work.